Fundacion CITA Alzheimer

Research site

Spain Pasealeku Mikeletegi 71, 20009 Donostia / San Sebastian, Spain

1 trial recruiting
Dementia Alzheimer's type · Prodromal Alzheimer's disease · Dementia of the Alzheimer's type uncomplicated
Adult patients

About Specializations

Fundacion CITA Alzheimer in Donostia / San Sebastian, Spain specialises in clinical trials of conditions such as Dementia Alzheimer's type, Prodromal Alzheimer's disease, Dementia of the Alzheimer's type uncomplicated, Trisomy 21, and other specialisations. This site conducts important research.

Main research areas of the site

Alzheimer's Disease Research

The medical center is at the forefront of Alzheimer's Disease research, focusing on innovative treatments and interventions. The center's commitment to understanding and combating this neurodegenerative disorder is evident through its extensive clinical trials and studies.

Long-term Safety and Tolerability of AL002
Cognitive Performance with XPro1595
Efficacy of BAN2401 in Early Alzheimer's
Preclinical Alzheimer's Disease Studies
GSK4527226 Efficacy in Early Alzheimer's
Sabirnetug for Cognitive Decline

Through these studies, the center is advancing the understanding of biomarkers and therapeutic targets, contributing significantly to the development of effective treatments for Alzheimer's Disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Pasealeku Mikeletegi 7120009 Donostia / San SebastianSpain

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 4

More sites in Donostia / San Sebastian Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

8 clinical trials

Trisomy 21+1

Recruiting

Study of levetiracetam to prevent seizures in adults who have both Down syndrome and Alzheimer's disease

Registered drug

Study of levetiracetam to prevent seizures in adults who have both Down syndrome and Alzheimer's disease

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Levetiracetam
Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Contact Research Centre

Prodromal Alzheimer's disease

Not yet recruiting

Efficacy and Safety of Trontinemab with [18F]MK-6240 in Cognitively Unimpaired Individuals at Risk for Alzheimer’s Disease

Investigational

Efficacy and Safety of Trontinemab with [18F]MK-6240 in Cognitively Unimpaired Individuals at Risk for Alzheimer’s Disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Florquinitau (18F)
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer's Disease

Registered drug

Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer's Disease

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Study of BAN2401 (lecanemab) in people with early stage Alzheimer's disease to evaluate its effectiveness in preventing disease progression

Registered drugNo placebo

Study of BAN2401 (lecanemab) in people with early stage Alzheimer's disease to evaluate its effectiveness in preventing disease progression

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Florquinitau (18F)
Sponsor:Eisai Limited

Contact Research Centre

Dementia Alzheimer's type+1

Not recruiting

Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer's Disease: Testing Safety and Effectiveness Over 18 Months

InvestigationalNo placebo

Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer's Disease: Testing Safety and Effectiveness Over 18 Months

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Lecanemab
Sponsor:Eisai Limited

Contact Research Centre

Dementia of the Alzheimer's type uncomplicated

Not recruiting

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Pegipanermin
Sponsor:Inmune Bio Inc.

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Study on the Long-term Safety and Effects of AL002 and Florquinitau F18 in Patients with Alzheimer's Disease

Investigational

Study on the Long-term Safety and Effects of AL002 and Florquinitau F18 in Patients with Alzheimer's Disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Florquinitau (18F)
Sponsor:Alector LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites